Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Methotrexate 9Cyclophosphamide 9fludarabine phosphate 7Vincristine 7Rituximab 7Tacrolimus 6Cytarabine 6nelarabine 5Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Filgrastim 5Dexamethasone 5Antilymphocyte Serum 5pegaspargase 4merphos 4Prednisone 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Calcium Dobesilate 4tanespimycin 3dexamethasone acetate 3dexamethasone 21-phosphate 3Radiotherapy 3Lenalidomide 3Doxorubicin 3Busulfan 3Bortezomib 3prednylidene 2deltacortene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × azathiopurine × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡